【摘要】 目的探讨Ⅱ~Ⅲ期非小细胞肺癌(NSCLC)患者肿瘤组织中MMP-3和TIMP-3的表达与术后接受含铂药物辅助化疗疗效的相关性。方法应用免疫组化方法检测112例NSCLC患者术后肿瘤组织中MMP-3和TIMP-3的表达,分析与化疗疗效和患者生存资料间的关系。结果患者肿瘤组织中MMP-3阳性率为56.25%,TIMP-3阳性率为47.32%,MMP-3阴性者术后生存优于阳性者;TIMP-3阴性者的术后生存低于阳性者(均P<0.01)。MMP-3阴性同时TIMP-3阳性的患者术后使用铂类药物辅助化疗,生存时间可能延长。结论 MMP-3和TIMP-3的表达可能作为NSCLC患者术后铂类药物化疗疗效及预后预测的参考指标。更多还原

【Abstract】 Objective To investigate the expression of MMP-3,TIMP-3 in patients with non-small cell lung cancer(NSCLC) and its relation to the prognosis after chemotherapy.Methods Expression of MMP-3 and TIMP-3 in 112 paraffin-embedded pathological specimens of NSCLC were determined by immunohistochemistry method.All patients received platinum-based adjuvant chemotherapy after operation.The association of MMP-3 and TIMP-3 expression with response to chemotherapy and survival of patients were analyzed.Results Positive expression rates of MMP-3 and TIMP-3 were 56.25%and 47.32%in NSCLC patients,respectively.The survival time in MMP-3 negative group was longer than that in MMP-3 positive group(P<0.01) and in TIMP-3 negative group was shorter than that in TIMP-3 positive group(P<0.01).Patients with negative expression of MMP-3 and positive expression of TIMP-3 showed a trend of improved survival time under platinum-based adjuvant chemotherapy.Conclusion The expression of MMP-3 and TIMP-3 is closely correlated with the survival time of NSCLC after adjuvant chemotherapy,indicating that MMP-3 and TIMP-3 can be used as molecular makers for prognosis f NSCLC patients.更多还原